Newsroom
A recent study by researchers at the University of Cyprus (UCY) in collaboration with the University of Oxford has unveiled promising medical applications for cancer and rare genetic disease treatments. Published in Science Advances, the research identifies a novel role for the ATR protein, traditionally known for its involvement in DNA damage repair, which also enhances the resilience of the cell nucleus against mechanical forces.
The study explains that ATR moves to the nuclear envelope, activating a mechanism that forms a protective network of proteins called nuclear actin. This internal support is crucial for reinforcing the nucleus, particularly in tissues subjected to constant mechanical stress, such as the lungs, heart, and muscles.
Dr. Maria Chatzifrangkeskou, the lead author, emphasized the clinical significance of these findings. She noted that the research could pave the way for new treatments for diseases characterized by nuclear fragility, including muscular dystrophies, progeria, and aggressive cancers. When cells lack robust protective mechanisms, they become more vulnerable to damage, worsening these conditions.
The implications of targeting the ATR protein are substantial. In cancer therapy, improving nuclear resilience could hinder cancer cell metastasis and potentially increase survival rates. Additionally, manipulating nuclear actin dynamics may provide new strategies for gene therapy.
Dr. Chatzifrangkeskou stated, “Our findings radically change how we perceive ATR,” emphasizing its importance in protecting the nucleus beyond its established role in DNA repair.
Read the article here:
ATR-hippo drives force signaling to nuclear F-actin and links mechanotransduction to neurological disorders
